Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of “Moderate Buy” from Analysts
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective […]
More Stories
Trump Says US Has Seized Oil Tanker Off Coast of Venezuela
By Jack Phillips President Donald Trump said on Dec. 10 that the United States seized an oil tanker off the...
Land Along Southern Border Is Transferred to Navy to Become Part of ‘National Defense Area’
By Jacob Burg The Trump administration said on Dec. 10 that it would transfer roughly 760 acres of public land...
We’ve Just Seen the Best Quarter in 3 Years (In Revenues) or 4 Years (Earnings)
By Louis Navellier I wrote this last weekend aboard the forty-fourth Forbes Cruise for Investors, where there was a high...
New Bipartisan Bills Aim to Raise Penalties for Online Child Abuse, Sextortion
By Savannah Hulsey Pointer Lawmakers announced on Dec. 9 three new bipartisan bills to address online violence and sexual abuse...
British Soldier Killed in Ukraine Watching Training Exercise
By Jill McLaughlin A British soldier was killed in Ukraine on Dec. 9 while watching a training exercise, the UK...
FDA Investigating Deaths Potentially Linked to COVID-19 Vaccines Across Age Ranges
By Aldgra Fredly The U.S. Food and Drug Administration (FDA) is looking into the potential links between COVID-19 vaccination and...